This small molecule was previously tested on several CRC cell lines harboring mutant and wild-type KRAS genes as a single drug and demonstrates superior growth inhibition activity toward oxaliplatin-resistant cells (Poloznikov et al., 2019; Huntington et al., 2021). Here, KRAS is linked to colorectal carcinoma.